CN114181312A - 半乳糖改造的免疫球蛋白1抗体 - Google Patents

半乳糖改造的免疫球蛋白1抗体 Download PDF

Info

Publication number
CN114181312A
CN114181312A CN202111538475.2A CN202111538475A CN114181312A CN 114181312 A CN114181312 A CN 114181312A CN 202111538475 A CN202111538475 A CN 202111538475A CN 114181312 A CN114181312 A CN 114181312A
Authority
CN
China
Prior art keywords
antibodies
population
antibody
relative frequency
galactose
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202111538475.2A
Other languages
English (en)
Chinese (zh)
Inventor
S·马利克
D·罗伊施
A·施努尔里格
M·L·特哈达
M·托曼
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
F Hoffmann La Roche AG
Original Assignee
F Hoffmann La Roche AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by F Hoffmann La Roche AG filed Critical F Hoffmann La Roche AG
Publication of CN114181312A publication Critical patent/CN114181312A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/32—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P21/00—Preparation of peptides or proteins
    • C12P21/005—Glycopeptides, glycoproteins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
    • C07K2317/41—Glycosylation, sialylation, or fucosylation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Biophysics (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Oncology (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Microbiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
CN202111538475.2A 2014-09-10 2015-09-04 半乳糖改造的免疫球蛋白1抗体 Pending CN114181312A (zh)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
EP14184201.3 2014-09-10
EP14184201 2014-09-10
US201462095912P 2014-12-23 2014-12-23
US62/095,912 2014-12-23
PCT/EP2015/070285 WO2016037947A1 (en) 2014-09-10 2015-09-04 Galactoengineered immunoglobulin 1 antibodies
CN201580048480.1A CN106687481B (zh) 2014-09-10 2015-09-04 半乳糖改造的免疫球蛋白1抗体

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
CN201580048480.1A Division CN106687481B (zh) 2014-09-10 2015-09-04 半乳糖改造的免疫球蛋白1抗体

Publications (1)

Publication Number Publication Date
CN114181312A true CN114181312A (zh) 2022-03-15

Family

ID=51518624

Family Applications (2)

Application Number Title Priority Date Filing Date
CN202111538475.2A Pending CN114181312A (zh) 2014-09-10 2015-09-04 半乳糖改造的免疫球蛋白1抗体
CN201580048480.1A Expired - Fee Related CN106687481B (zh) 2014-09-10 2015-09-04 半乳糖改造的免疫球蛋白1抗体

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN201580048480.1A Expired - Fee Related CN106687481B (zh) 2014-09-10 2015-09-04 半乳糖改造的免疫球蛋白1抗体

Country Status (5)

Country Link
US (2) US20170253661A1 (enExample)
EP (2) EP3567056A1 (enExample)
JP (1) JP2017528468A (enExample)
CN (2) CN114181312A (enExample)
WO (1) WO2016037947A1 (enExample)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2019006266A (es) * 2016-12-21 2019-08-21 Hoffmann La Roche Glucomanipulacion in vitro de anticuerpos.
MX2019006123A (es) * 2016-12-21 2019-08-12 Hoffmann La Roche Metodo para glicomanipulacion in vitro de anticuerpos.
JP6931058B2 (ja) 2016-12-21 2021-09-01 エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ 抗体のインビトロ糖鎖工学における酵素の再使用
EP3850006A1 (en) * 2018-09-11 2021-07-21 Amgen Inc. Methods of modulating antibody-dependent cell-mediated cytotoxicity
US20240092935A1 (en) * 2019-10-11 2024-03-21 Beth Israel Deaconess Medical Center, Inc. Anti-tn antibodies and uses thereof
EP4204005A1 (en) 2020-08-31 2023-07-05 Sab, Llc Ungulate-derived polyclonal immunoglobulin specific for coronavirus protein and uses thereof
EP4119672A1 (en) * 2021-07-14 2023-01-18 Sartorius Stedim Cellca GmbH Method of modulating the extent of galactosylation of proteins in mammalian producer cells
CN114167060B (zh) * 2021-11-25 2022-08-05 辽宁师范大学 一种肝癌生物标志物及检测肝癌的试剂盒
US20250320279A1 (en) * 2021-11-30 2025-10-16 Sab, Llc Ungulate-derived polyclonal immunoglobulin specific for influenza virus and uses thereof

Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070015239A1 (en) * 2003-10-20 2007-01-18 Laboratoire Francais Du Fractionnement Et Des Biotechnologies Correlation between the fucose content/galactose content ratio of anti-rhesus-d and anti-hla-dr antibodies and the adcc activity
CN101646775A (zh) * 2006-12-28 2010-02-10 森托科尔奥索生物技术公司 用于产生脱唾液酸化免疫球蛋白的方法和载体
US20110263828A1 (en) * 2009-12-02 2011-10-27 Academia Sinica Methods for modifying human antibodies by glycan engineering
US20130071390A1 (en) * 2010-05-27 2013-03-21 Merck, Sharp & Dohme Corp Method for preparing antibodies having improved properties
WO2013050335A1 (en) * 2011-10-05 2013-04-11 F. Hoffmann-La Roche Ag Process for antibody g1 glycoform production
CN103119064A (zh) * 2010-08-10 2013-05-22 葛莱高托普有限公司 Fab糖基化抗体
WO2014125377A2 (en) * 2013-02-13 2014-08-21 Laboratoire Francais Du Fractionnement Et Des Biotechnologies Highly galactosylated anti-her2 antibodies and uses thereof

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL85035A0 (en) 1987-01-08 1988-06-30 Int Genetic Eng Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same
JP3040121B2 (ja) 1988-01-12 2000-05-08 ジェネンテク，インコーポレイテッド 増殖因子レセプターの機能を阻害することにより腫瘍細胞を処置する方法
CA2103059C (en) 1991-06-14 2005-03-22 Paul J. Carter Method for making humanized antibodies
US5736137A (en) 1992-11-13 1998-04-07 Idec Pharmaceuticals Corporation Therapeutic application of chimeric and radiolabeled antibodies to human B lymphocyte restricted differentiation antigen for treatment of B cell lymphoma
DK1516628T3 (da) 1995-07-27 2013-09-08 Genentech Inc Stabil, isotonisk lyofiliseret proteinformulering
GB9603256D0 (en) * 1996-02-16 1996-04-17 Wellcome Found Antibodies
DK1068241T3 (da) 1998-04-02 2008-02-04 Genentech Inc Antistofvarianter og fragmenter deraf
US6194551B1 (en) 1998-04-02 2001-02-27 Genentech, Inc. Polypeptide variants
KR100960211B1 (ko) 1998-05-06 2010-05-27 제넨테크, 인크. 이온 교환 크로마토그래피에 의한 단백질 정제 방법
US6737056B1 (en) 1999-01-15 2004-05-18 Genentech, Inc. Polypeptide variants with altered effector function
TR201809892T4 (tr) * 2003-11-05 2018-07-23 Roche Glycart Ag Fc reseptörüne bağlanma afinitesi ve artırılmış efektör fonksiyonu bulunan antijen bağlayan moleküller.
DK1896071T3 (en) * 2005-06-30 2015-05-26 Janssen Biotech Inc Methods and compositions with increased therapeutic activity
JP6433786B2 (ja) * 2011-08-10 2018-12-05 ラボラトワール フランセ デュ フラクショヌマン エ デ ビオテクノロジーＬａｂｏｒａｔｏｉｒｅ Ｆｒａｎｃａｉｓ ｄｕ Ｆｒａｃｔｉｏｎｎｅｍｅｎｔ ｅｔ ｄｅｓ Ｂｉｏｔｅｃｈｎｏｌｏｇｉｅｓ 高度ガラクトシル化抗体

Patent Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070015239A1 (en) * 2003-10-20 2007-01-18 Laboratoire Francais Du Fractionnement Et Des Biotechnologies Correlation between the fucose content/galactose content ratio of anti-rhesus-d and anti-hla-dr antibodies and the adcc activity
CN101646775A (zh) * 2006-12-28 2010-02-10 森托科尔奥索生物技术公司 用于产生脱唾液酸化免疫球蛋白的方法和载体
US20110263828A1 (en) * 2009-12-02 2011-10-27 Academia Sinica Methods for modifying human antibodies by glycan engineering
US20130071390A1 (en) * 2010-05-27 2013-03-21 Merck, Sharp & Dohme Corp Method for preparing antibodies having improved properties
CN103119064A (zh) * 2010-08-10 2013-05-22 葛莱高托普有限公司 Fab糖基化抗体
WO2013050335A1 (en) * 2011-10-05 2013-04-11 F. Hoffmann-La Roche Ag Process for antibody g1 glycoform production
WO2014125377A2 (en) * 2013-02-13 2014-08-21 Laboratoire Francais Du Fractionnement Et Des Biotechnologies Highly galactosylated anti-her2 antibodies and uses thereof

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
DAMIAN HOUDE等: "Post-translational modifications differentially affect IgG1 conformation and receptor binding", 《MOL CELL PROTEOMICS》, vol. 9, no. 8, pages 1716 - 1728, XP055169032, DOI: 10.1074/mcp.M900540-MCP200 *
TOYOHIDE SHINKAWA等: "The absence of fucose but not the presence of galactose or bisecting N-acetylglucosamine of human IgG1 complex-type oligosaccharides shows the critical role of enhancing antibody-dependent cellular cytotoxicity", 《J BIOL CHEM》, vol. 278, no. 2, pages 3466 - 3473 *
陈玉强;王元;: "丙种免疫球蛋白Fc段糖基化及其生物学活性和功能", 现代生物医学进展, no. 07 *

Also Published As

Publication number Publication date
WO2016037947A1 (en) 2016-03-17
CN106687481A (zh) 2017-05-17
EP3191527B1 (en) 2020-01-15
US20200325245A1 (en) 2020-10-15
CN106687481B (zh) 2022-03-22
EP3567056A1 (en) 2019-11-13
EP3191527A1 (en) 2017-07-19
US20170253661A1 (en) 2017-09-07
JP2017528468A (ja) 2017-09-28

Similar Documents

Publication Publication Date Title
CN106687481B (zh) 半乳糖改造的免疫球蛋白1抗体
CA2674239C (en) Methods and vectors for generating asialylated immunoglobulins
AU2006265676B2 (en) Methods and compositions with enhanced therapeutic activity
US20120076778A1 (en) Antibodies Against Insulin-Like Growth Factor I Receptor and Uses Thereof
EP3559248B1 (en) In vitro glycoengineering of antibodies
JP2014508759A (ja) シアリル化抗体の生産の方法
TWI781973B (zh) 用於以活體外進行抗體糖基化工程之方法
US20250313646A1 (en) Glycoengineered antibodies
JP2021006540A (ja) ガラクトース操作型免疫グロブリン１抗体
HK1241889A1 (en) Galactoengineered immunoglobulin 1 antibodies
CN101466402A (zh) 糖基化改造的抗体治疗
HK40011889A (en) In vitro glycoengineering of antibodies
HK1134829A (en) Antibodies against insulin-like growth factor i receptor and uses thereof

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
WD01 Invention patent application deemed withdrawn after publication

Application publication date: 20220315

WD01 Invention patent application deemed withdrawn after publication